Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD) Dialysis Patients Using MDGN201 TARGTEPO

NCT02117427 is registered in ClinicalTrials.gov with Aevi Genomic Medicine, LLC, a Cerecor company as lead sponsor.

NCT NCT02117427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02117427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD) Dialysis Patients Using MDGN201 TARGTEPO
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Phase
Phase 1/2
Overall status
Completed
Start date
May 27, 2014
Completion date
March 20, 2017
Enrollment
11 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, end stage renal disease